pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

APOTEX

USupdated 3mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Unknown: 3
3Unknown
drug
IVRA
drug
REGADENOSON
drug
VAROPHEN

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view APOTEX jobs →

News

  • Rebounding biotech funds expected to spur CDMO growth within year
    With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
    biospace · 1mo ago
  • STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
    Sandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.
    stat · 1mo ago
  • Trump threatens tariffs on imported generic drugs
    While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove mor…
    biopharma_dive · 1mo ago
  • STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states
    Glenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations in a long-running battle with dozens of states.
    stat · 2mo ago
identifiers
country
US
source
openfda_drugsfda
mentioned in
4news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?